Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma

Phase 2 Completed 60 enrolled Barbara Ann Karmanos Cancer Institute National Cancer Institute (NCI) · collab

Open-labelTreatment

Summary

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of biological therapy following surgery and radiation therapy in treating patients who have primary or recurrent astrocytoma or oligodendroglioma.

Timeline

Start: 1997-06
Primary completion: 2004-01
Completion: 2004-01

Publications

Results Sloan AE, Dansey R, Zamorano L, Barger G, Hamm C, Diaz F, Baynes R, Wood G. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg Focus. 2000 Dec 15;9(6):e9. doi: 10.3171/foc.2000.9.6.10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	aldesleukin	Protein / enzyme biologic	—	Intravenous
Subject	autologous tumor cell vaccine	Vaccine	—	—
Subject	sargramostim	Protein / enzyme biologic	—	Intravenous
Subject	therapeutic autologous lymphocytes	Cell therapy	—	Intravenous
Background	muromonab-CD3	Monoclonal antibody	—	—

Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma

Summary

Timeline

Publications

Drugs

Indications